Experimental demonstration of measurement-device-independent measure of quantum steering

Within the framework of quantum refereed steering games, quantum steerability can be certified without any assumption on the underlying state nor the measurements involved. Such a scheme is termed the measurement-device-independent (MDI) scenario. Here, we introduce a measure of steerability in an MDI scenario, i.e., the result merely depends on the observed statistics and the quantum inputs. We prove that such a measure satisfies the convex steering monotone. Moreover, it is robust against not only measurement biases but also losses. We also experimentally estimate the amount of the measure with an entangled photon source. As two by-products, our experimental results provide lower bounds on an entanglement measure of the underlying state and an incompatible measure of the involved measurement. Our research paves a way for exploring one-side device-independent quantum information processing within an MDI framework

Device-independent verification of Einstein-Podolsky-Rosen steering

If the presence of entanglement could be certified in a device-independent (DI) way, it is likely to provide various quantum information processing tasks with unconditional security. Recently, it was shown that a DI protocol, combining measurement-device-independent techniques with self-testing, is able to verify all entangled states, however, it imposes demanding requirements on its practical implementation. Here, we present a less-demanding protocol based on Einstein-Podolsky-Rosen (EPR) steering, which is achievable with current technology. Particularly, we first establish a complete framework for DI verification of EPR steering and show that all steerable states can be verified. Then, we analyze the three-measurement setting case, allowing for imperfections of self-testing. Finally, a four-photon experiment is implemented to device-independently verify EPR steering and to further demonstrate that even Bell local states can be faithfully verified. Our findings pave the way for realistic applications of secure quantum information tasksComment: 6+8 pages; Comments are welcom

Lattice QCD evaluation of the Compton amplitude employing the Feynman-Hellmann theorem

Published 8 December 2020The forward Compton amplitude describes the process of virtual photon scattering from a hadron and provides an essential ingredient for the understanding of hadron structure. As a physical amplitude, the Compton tensor naturally includes all target mass corrections and higher twist effects at a fixed virtuality, Q². By making use of the second-order Feynman-Hellmann theorem, the nucleon Compton tensor is calculated in lattice QCD at an unphysical quark mass across a range of photon momenta 3 ≲ Q² ≲ 7 GeV². This allows for the Q² dependence of the low moments of the nucleon structure functions to be studied in a lattice calculation for the first time. The results demonstrate that a systematic investigation of power corrections and the approach to parton asymptotics is now within reach.K. U. Can, A. Hannaford-Gunn, R. Horsley, Y. Nakamura, H. Perlt, P. E. L. Rakow, G. Schierholz, K. Y. Somfleth, H. Stüben, R. D. Young, and J. M. Zanotti (QCDSF/UKQCD/CSSM Collaborations

Do asian patients require only half of the clozapine dose prescribed for caucasians? A critical overview

© 2020 Indian Psychiatric Society - South Zonal Branch | Published by Wolters Kluwer - Medknow. Since 1997, studies have found that Asians need lower clozapine doses than Caucasians. Caucasians with average clozapine metabolism may need from 300 to 600 mg/day to reach the therapeutic range (350 ng/ml). Thus, serum clozapine concentration-to-dose (C/D) ratios typically range between 0.60 (male smokers) and 1.20 (female non-smokers). A 2019 systematic review of clozapine levels demonstrated weighted mean C/D ratios of 1.57 in 876 East Asians and 1.07 in 1147 Caucasians (

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories.Methods: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age.Findings: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran.Interpretation: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings.Copyright (C) 2021 World Health Organization; licensee Elsevier.</p